Last reviewed · How we verify
Fibrin sealant (FS2)
Fibrin sealant (FS2) is a topical hemostatic agent that forms a fibrin clot to seal wounds and control bleeding during surgical procedures.
Fibrin Sealant 2 (FS2) by Ethicon, Inc. is a surgical adhesive evaluated in Phase 3 trials for retroperitoneal, intra-abdominal, and vascular surgeries. No FDA label, but strong clinical evidence supports its use in reducing bleeding and promoting tissue adhesion.
At a glance
| Generic name | Fibrin sealant (FS2) |
|---|---|
| Sponsor | Ethicon, Inc. |
| Drug class | Hemostatic agent / Fibrin sealant |
| Modality | Small molecule |
| Therapeutic area | Surgery / Hemostasis |
| Phase | Phase 3 |
Mechanism of action
FS2 combines human fibrinogen and thrombin to create a physiologic fibrin clot at the site of application, mimicking the final step of the coagulation cascade. This provides rapid hemostasis and tissue adhesion, reducing bleeding and promoting wound healing in surgical settings. The fibrin matrix is gradually absorbed and replaced by natural tissue repair processes.
Approved indications
- Hemostasis and tissue sealing in general surgery
- Hemostasis in cardiovascular surgery
- Hemostasis in orthopedic surgery
Common side effects
- Allergic reaction
- Infection at application site
- Thrombosis (rare)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fibrin sealant (FS2) CI brief — competitive landscape report
- Fibrin sealant (FS2) updates RSS · CI watch RSS
- Ethicon, Inc. portfolio CI